The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Interim analysis of a Phase II study of pirtobrutinib + venetoclax in previously treated WM
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the promising results of a Phase II study (NCT05734495) evaluating the combination of pirtobrutinib and venetoclax in previously treated patients with Waldenström’s macroglobulinemia (WM). Dr Castillo highlights that the study has shown a 65% very good partial response (VGPR) rate in the first 16 patients enrolled and that the combination has been well-tolerated with no unexpected side effects. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
